Omeros Corporation (NASDAQ:OMER - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Omeros in a report released on Wednesday, July 23rd. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will post earnings per share of ($2.14) for the year, down from their previous estimate of ($2.04). The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros' FY2026 earnings at ($1.16) EPS.
A number of other analysts also recently weighed in on the company. D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research report on Monday, June 30th. HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Omeros in a research note on Friday, June 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research note on Friday, May 16th. Finally, Wall Street Zen downgraded Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $18.00.
Read Our Latest Report on Omeros
Omeros Stock Down 6.0%
OMER stock opened at $3.59 on Friday. The firm has a market capitalization of $210.34 million, a PE ratio of -1.35 and a beta of 2.16. The stock has a 50-day simple moving average of $3.35 and a two-hundred day simple moving average of $6.36. Omeros has a twelve month low of $2.95 and a twelve month high of $13.60.
Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05).
Institutional Trading of Omeros
Several institutional investors and hedge funds have recently added to or reduced their stakes in OMER. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 1,110 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Omeros by 4.9% during the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock worth $345,000 after purchasing an additional 1,973 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Omeros by 2.0% during the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock worth $1,190,000 after purchasing an additional 2,317 shares during the last quarter. Finally, Cerity Partners LLC lifted its stake in shares of Omeros by 9.9% during the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 2,600 shares during the last quarter. Institutional investors own 48.79% of the company's stock.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.